Advanced primary care may be one of employers' strongest tools for catching cancer earlier, and better support during and ...

Yesterday, September 24, the FDA approved the combination of belzutifan (WELIREG; Merck) plus lenvatinib (LENVIMA; Eisai) to ...

Sophy Levine, PharmD, discusses how an integrated health system specialty pharmacy may help lower 1-year GLP-1 discontinuation.

Safety-net claims emphasize disproportionate Medicaid and uncompensated care borne by 340B hospitals, whereas other analyses ...

Community oncology practices face steep structural barriers to clinical trial enrollment, and pragmatic trial design that ...

FDA movement of peptides toward 503A bulks listing advanced despite internal scientific objections citing absent human ...

Regulatory volatility since 2020, including IRA price negotiation, MFN pricing directives, and Medicaid best-price dynamics, ...

Prior authorization remains the dominant friction point, with nearly universal reporting of delays that widen the gap between ...

Adaolisa Anaka, PharmD, BCACP, AAHIVP, discusses a pharmacist-led model that targets access barriers to GLP-1 obesity therapy. Glucagon-like peptide-1 (GLP-1) receptor agonists have become a key ...

She also predicted that drug pricing, more than access algorithms, will determine which GLP-1 becomes first-line within the ...

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care. Patients receiving injectable glucagon-like peptide-1 receptor agonist (GLP-1 ...